The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Noradrenergic dysfunction in Alzheimer's disease
Open accessAbstract
The brain noradrenergic system supplies the neurotransmitter norepinephrine throughout the brain via widespread efferent projections, and plays a pivotal role in modulating cognitive activities in the cortex. Profound noradrenergic degeneration in Alzheimer's disease (AD) patients has been observed for decades, with recent research suggesting that the locus coeruleus (where noradrenergic neurons are mainly located) is a predominant site where AD-related pathology begins. Mounting evidence indicates that the loss of noradrenergic innervation greatly exacerbates AD pathogenesis and progression, although the precise roles of noradrenergic components in AD pathogenesis remain unclear. The aim of this review is to summarize current findings on noradrenergic dysfunction in AD, as well as to point out deficiencies in our knowledge where more research is needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The hippocampus and memory: insights from spatial processing
Bird, C. M., & Burgess, N. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2335 · Cited by 1,313
The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease
Rogaeva, E., Meng, Y., Lee, J. H., Gu, Y., Kawarai, T., Zou, F., Katayama, T., Baldwin, C. T., Cheng, R., Hasegawa, H., et al. (2007) · Nature Genetics · doi:10.1038/ng1943 · Cited by 1,167
Wang, M., Ramos, B. P., Paspalas, C. D., Shu, Y., Simen, A., Duque, A., Vijayraghavan, S., Brennan, A., Dudley, A., Nou, E., et al. (2007) · Cell · doi:10.1016/j.cell.2007.03.015 · Cited by 672
Arnsten, A. F. T., & Goldman-Rakic, P. S. (1985) · Science · doi:10.1126/science.2999977 · Cited by 549 · cited 1×
“Clonidine and guanfacine can improve working memory in aged monkeys with documented memory impairment (Arnsten and Goldman-Rakic, 1985, 1987; Arnsten et al., 1988).”
BackgroundAlzheimer Disease and Oxidative Stress
Perry, G., Cash, A. D., & Smith, M. A. (2002) · BioMed Research International · doi:10.1155/s1110724302203010 · Cited by 455 · cited 1×
“Another symptom of AD is aberrant glucose metabolism (Schubert, 2005), which can be seen in the increased levels of oxidative stress in AD patients that occurs before the appearance of Aβ plaques (Perry et al., 2002). α1 receptors on astrocytes regulate glucose uptake.”
BackgroundEimer, W. A., & Vassar, R. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-2 · Cited by 425 · cited 2×
“We provide a brief overview of the literature here as an introduction to the role of the noradrenergic system in AD, but we are aware that we have not mentioned all relevant papers to this topic.”
BackgroundO’Donnell, J., Zeppenfeld, D., McConnell, E., Pena, S., & Nedergaard, M. (2012) · Neurochemical Research · doi:10.1007/s11064-012-0818-x · Cited by 399
Grudzien, A., Shaw, P., Weintraub, S., Bigio, E., Mash, D. C., & Mesulam, M. M. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.02.007 · Cited by 396 · cited 2×
“Indeed, evidence from both human patients and animal models indicates that loss of noradrenergic innervation greatly exacerbates AD pathogenesis and progression (Marien et al., 2004; Heneka et al., 2006; Grudzien et al., 2007; Kalinin et al., 2007; Pugh et al., 2007).”
BackgroundInfluentialArnsten, A., Cai, J., & Goldman-Rakic, P. (1988) · The Journal of Neuroscience · doi:10.1523/jneurosci.08-11-04287.1988 · Cited by 391 · cited 1×
“Clonidine and guanfacine can improve working memory in aged monkeys with documented memory impairment (Arnsten and Goldman-Rakic, 1985, 1987; Arnsten et al., 1988).”
BackgroundLoss of apolipoprotein E receptor LR11 in Alzheimer disease
Scherzer, C. R., Offe, K., Gearing, M., Rees, H. D., Fang, G., Heilman, C. J., Schaller, C., Bujo, H., Levey, A. I., & Lah, J. J. (2004) · Archives of Neurology · doi:10.1001/archneur.61.8.1200 · Cited by 316 · cited 2×
“This indicates that the adrenergic receptors play a large role in the balance of glycogen in the brain and, therefore, could potentially be targeted to improve the aberrant glucose metabolism seen in AD.”
BackgroundHeneka, M. T., Ramanathan, M., Jacobs, A. H., Dumitrescu-Ozimek, L., Bilkei-Gorzo, A., Debeir, T., Sastre, M., Galldiks, N., Zimmer, A., Hoehn, M., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4236-05.2006 · Cited by 305 · cited 4×
“Indeed, evidence from both human patients and animal models indicates that loss of noradrenergic innervation greatly exacerbates AD pathogenesis and progression (Marien et al., 2004; Heneka et al., 2006; Grudzien et al., 2007; Kalinin et al., 2007; Pugh et al., 2007).”
BackgroundInfluentialPottier, C., Hannequin, D., Coutant, S., Rovelet-Lecrux, A., Wallon, D., Rousseau, S., Legallic, S., Paquet, C., Bombois, S., Pariente, J., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.15 · Cited by 305
Gamo, N. J., Wang, M., & Arnsten, A. F. T. (2010) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2010.06.015 · Cited by 232 · cited 2×
“Additionally, improvements in working memory (Gamo et al., 2010) and attention (Tzavara et al., 2006; Jentsch et al., 2009) have been seen after atomoxetine treatment.”
BackgroundLiu, Y., Yoo, M.-J., Savonenko, A., Stirling, W., Price, D. L., Borchelt, D. R., Mamounas, L., Lyons, W. E., Blue, M. E., & Lee, M. K. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4218-08.2008 · Cited by 206 · cited 2×
“We provide a brief overview of the literature here as an introduction to the role of the noradrenergic system in AD, but we are aware that we have not mentioned all relevant papers to this topic.”
BackgroundNEURONAL DEGENERATION IN LOCUS CERULEUS AND CORTICAL CORRELATES OF ALZHEIMER DISEASE
Bondareff, W., Mountjoy, C. Q., Roth, M., Rossor, M. N., Iversen, L. L., Reynolds, G. P., & Hauser, D. L. (1987) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-198701040-00005 · Cited by 166 · cited 1×
“In AD patients, the extent of noradrenergic degeneration correlates with both the degree of pathological changes (including amyloid plaques and neurofibrillary tangles) and the severity of cognitive deficits (Bondareff et al., 1987; Zarow et al., 2003).”
BackgroundCai, J. X., Ma, Y.-Y., Xu, L., & Hu, X.-T. (1993) · Brain Research · doi:10.1016/0006-8993(93)91034-p · Cited by 122 · cited 1×
“Treating monkeys with reserpine also induces a working memory deficit (Cai et al., 1993).”
BackgroundThe noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer’s disease
Kalinin, S., Polak, P. E., Lin, S. X., Sakharkar, A. J., Pandey, S. C., & Feinstein, D. L. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.04.012 · Cited by 116 · cited 2×
“Co-administering L-DOPS along with atomoxetine, a norepinephrine reuptake inhibitor, in 5xFAD transgenic mice improves learning in the Morris water maze test (Kalinin et al., 2012).”
BackgroundExpression of SORL1 and a novel SORL1 splice variant in normal and Alzheimers disease brain
Grear, K. E., Ling, I.-F., Simpson, J. F., Furman, J. L., Simmons, C. R., Peterson, S. L., Schmitt, F. A., Markesbery, W. R., Liu, Q., Crook, J. E., et al. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-46 · Cited by 56
Antihypertensive Medication Use and Incident Alzheimer Disease: The Cache County Study
Khachaturian, A. S. (2006) · Archives of Neurology · doi:10.1001/archneur.63.5.noc60013 · Cited by 3 · cited 2×
“This indicates that the adrenergic receptors play a large role in the balance of glycogen in the brain and, therefore, could potentially be targeted to improve the aberrant glucose metabolism seen in AD.”
BackgroundIncreased activity of surviving locus ceruleus neurons in Alzheimer's disease
Moser (1999) · Pure Amsterdam UMC · doi:10.1002/1531-8249(199901)45:1
Cited by
Govindpani, K., McNamara, L. G., Smith, N. R., Vinnakota, C., Waldvogel, H. J., Faull, R. L., & Kwakowsky, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050651 · Cited by 275
Combination Drug Therapy for the Management of Alzheimer’s Disease
Kabir, M. T., Uddin, M. S., Mamun, A. A., Jeandet, P., Aleya, L., Mansouri, R. A., Ashraf, G. M., Mathew, B., Bin-Jumah, M. N., & Abdel-Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093272 · Cited by 217
Reimagining cholinergic therapy for Alzheimer’s disease
Giacobini, E., Cuello, A. C., & Fisher, A. (2022) · Brain · doi:10.1093/brain/awac096 · Cited by 187
Chalermpalanupap, T., Schroeder, J. P., Rorabaugh, J. M., Liles, L. C., Lah, J. J., Levey, A. I., & Weinshenker, D. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.1483-17.2017 · Cited by 136
“Thus, as the sole source of NE to critical AD-associated brain regions, such as the hippocampus and frontal cortex, damage to the LC likely contributes to disease progression and severity (Mann, 1983; Zweig et al., 1989; Jalbert et al., 2008; Weinshenker, 2008; Gannon et al., 2015).”
Backgroundβ-amyloid redirects norepinephrine signaling to activate the pathogenic GSK3β/tau cascade
Zhang, F., Gannon, M., Chen, Y., Yan, S., Zhang, S., Feng, W., Tao, J., Sha, B., Liu, Z., Saito, T., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay6931 · Cited by 133
Self-citation
Metadata
- Authors
- Gannon, M., Che, P., Chen, Y., Jiao, K., Roberson, E. D., & Wang, Q.
- Venue
- Frontiers in Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2015-06-17
- Volume
- 9
- Pages
- 220-220
- ISSN
- 1662-453X (ISSN-L)
- OpenAlex
- W1583810538
- Cited by
- 209
- References
- 20
- FWCI
- 8.82
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.